Exhibit 99.1 HARMONY BIOSCIENCES REPORTS STRONG THIRD QUARTER 2024 FINANCIAL RESULTS AND HIGHLIGHTS CATALYST-RICH, LATE-STAGE PIPELINE POISED TO DELIVER ONE OR MORE NEW LAUNCHES EVERY YEAR OVER NEXT FIVE YEARS WAKIX (pitolisant) Net Revenue of $186.0 Million for Third Quarter 2024; Surpassed $2B in Cumulative Net Revenue in Less Than Five Years On Track to Submit sNDA for Pitolisant in Idiopathic Hypersomnia (IH) in Q4 2024 Based on Updated Strong and Sustained Efficacy Data from Long-Term Extension Study N ...

The market expects Harmony Biosciences Holdings, Inc. (HRMY) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which ...

文章核心观点 - 公司将于2024年10月29日发布第三季度财务业绩 [1] - 公司将于2024年10月29日上午8:30举行电话会议和网络直播,讨论第三季度财务业绩 [1] - 公司是一家专注于开发和商业化罕见神经系统疾病创新疗法的制药公司 [2] 公司概况 - 公司成立于2017年,总部位于宾夕法尼亚州普利茅斯会议 [2] - 公司由Paragon Biosciences, LLC创立 [2] - 公司致力于为罕见神经系统疾病患者提供未满足的医疗需求的创新疗法 [2] 联系方式 - 投资者联系人:Brennan Doyle [3] - 媒体联系人:Cate McCanless [3]

Harmony Biosciences Holdings, Inc. (HRMY) shares rallied 6.7% in the last trading session to close at $39.79. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 5.2% gain over the past four weeks. Last month, the company announced robust financial results for the second quarter of 2024. Harmony's approved product, Wakix (pitolisant) is driving revenues while the company is making good progress with the studies o ...

Harmony Biosciences Holdings, Inc. (HRMY) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and follo ...

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Harmony Biosciences Holdings, Inc. (HRMY) or Regeneron (REGN) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank is a prove ...

文章核心观点 - UBS 对 Harmony Biosciences Holdings Inc (HRMY) 发起了覆盖,这是一家专注于罕见神经系统疾病的商业阶段生物制药公司 [1] - 公司的上市药物 Wakix (pitolisant) 获批用于成人失眠症患者的过度日间嗜睡或嗜睡发作 [1] - Wakix 在 2024 年第二季度的净收入为 1.72.8 亿美元,同比增长 29% [1] - Wakix 的患者人数环比增加约 250 人,达到约 6,550 人 [1] - UBS 给予 Harmony 买入评级,目标价为 56 美元,认为 Wakix 有望持续增长 [1] 行业分析 公司业务 - Wakix 在嗜睡症市场的地位良好,有望受益于对该疾病认知度的提高,诊断率从目前的约 50% 有上升空间 [2] - Wakix 在多药联合治疗市场也有优势,相比其他已批准药物具有差异化特点 [2] - 公司最近的业务拓展交易可能为管线带来多元化的机会,如收购 Epygenix Therapeutics 获得罕见癫痫药物 Zygel [2] - Zygel 在脆性 X 综合征的III期临床试验有望取得积极结果,预计 2025 年中期公布数据 [2]

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers. Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by th ...

PLYMOUTH MEETING, Pa., Aug. 21, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences: Wells Fargo 2024 Healthcare Conference Location: Boston Fireside Chat: Thursday, September 5, 2024, at 9:30 a.m. ET 2024 Cantor Global Healthcare Conference Location: New York City Fireside Chat: Tuesday, September 17, 2024, at 3:05 p.m. ET A webcast of the fireside chats will be available on th ...

| --- | --- | --- | --- | |-----------------------------------------------------------------------------------------------------------------------------------|-------|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | | | | | ...